In breast cancer, treatment with ROS inducers (i.e., paclitaxel or buthionine sulphoximine) promotes the transcription of PD-L1 via NF-κB in TAMs, which in turn acquire an immunosuppressive phenotype and improve the efficacy of anti-PD-L1 antibody-based immunotherapy (Roux et al., 2019). This evidence concerns the gene CD274 and breast cancer.